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Abstract: Optic neuropathy is a frequent cause of vision loss encountered by ophthalmologist. 
The diagnosis is made on clinical grounds. The history often points to the possible etiology of the 
optic neuropathy. A rapid onset is typical of demyelinating, inﬂ  ammatory, ischemic and traumatic 
causes. A gradual course points to compressive, toxic/nutritional and hereditary causes. The 
classic clinical signs of optic neuropathy are visual ﬁ  eld defect, dyschromatopsia, and abnormal 
papillary response. There are ancillary investigations that can support the diagnosis of optic 
neuropathy. Visual ﬁ  eld testing by either manual kinetic or automated static perimetry is critical 
in the diagnosis. Neuro-imaging of the brain and orbit is essential in many optic neuropathies 
including demyelinating and compressive. Newer technologies in the evaluation of optic neu-
ropathies include multifocal visual evoked potentials and optic coherence tomography.
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Diagnosis
History
The mode of onset of visual loss is an important clue to the etiology of the optic 
neuropathy. Rapid onset is characteristic of optic neuritis, ischemic optic neuropathy, 
inﬂ  ammatory (non-demyelinating) and traumatic optic neuropathy. A gradual onset 
over months is typical of compressive toxic/nutritional optic neuropathy. A more 
protracted history over years is seen in compressive and hereditary optic neuropathies. 
The ophthalmologist should make an effort in eliciting history of associated symp-
toms that can help reﬁ  ne the differential diagnosis. In a young patient, history of eye 
pain associated with eye movement, prior history of neurological symptoms such as 
paresthesia, limb weakness, and ataxia is suggestive of demyelinating optic neuritis. 
These neurological complaints may have been misdiagnosed or dismissed by other 
physicians. For example, chronic arm paresthesia is usually initially misdiagnosed 
as “carpal tunnel syndrome”. Diminution of vision following a rise in body tempera-
ture such as following exercise or a hot shower is known as Uhthoff’s phenomenon. 
Although this symptom is usually associated with demyelinating optic neuropathy, it 
has been reported in a variety of other optic neuropathies including Leber’s heredi-
tary optic neuropathy, and optic neuropathy in sarcoidosis (Riordan-Eva et al 1995; 
Haupert and Newman 1997).
In an elderly with signs of optic neuropathy, the presence of preceding transient visual 
loss, diplopia, temporal pain, jaw claudications, fatigue, weight loss and myalgias is strongly 
suggestive of arteritic ischemic optic neuropathy (AION) due to giant cell arteritis (GCA). 
In children, history of recent ﬂ  u-like illness or vaccination days or weeks before vision loss 
points to a para-infectious or post-vaccinial optic neuritis, respectively.
Symptoms such as diplopia and facial pain are suggestive of multiple cranial 
neuropathies seen in inﬂ  ammatory or neoplastic lesions of the posterior orbit or Clinical Ophthalmology 2007:1(3) 234
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parasellar region. Transient visual obscurations (periods of 
vision blackouts lasting seconds caused by change in body 
position), transient diplopia and headache should raise the 
suspicion of increased intra-cranial pressure.
The use of any medications should be carefully noted 
since some are either directly or indirectly toxic to the optic 
nerve. These include drugs as ethambutol, amiodarone, 
alcohol, and immunosuppressive medications such as metho-
trexate and cyclosporine.
History of diabetes, hypertension and hypercholester-
olemia is common in patients with non-arteritic ischemic 
optic neuropathy (NAION). Patients who are being treated 
for or have history of malignancy may have inﬁ  ltrative or 
para-neoplastic optic neuropathy.
Inquiry into the patient’s general health, eating and 
social habits (drinking, smoking) is important in suspected 
toxic/nutritional optic neuropathy. A detailed family history 
is important in diagnosing hereditary autosomal and mito-
chondrial optic neuropathies.
Neuro-ophthalmic examination
Acute or chronic vision loss can be caused by any diseases of 
the anterior visual pathway including the retinal diseases. In 
many cases, the signs of retinopathy are subtle and it is dif-
ﬁ  cult to determine if the cause of vision loss is a retinopathy 
or optic neuropathy. Therefore, it is important to establish 
the classic signs of optic neuropathy; visual ﬁ  eld defect, 
decreased color vision, and the presence of relative afferent 
papillary defect (RAPD).
Visual acuity can be normal or impaired depending on 
whether the central visual ﬁ  eld is affected. In many cases, 
visual acuity is normal, yet the patient as a large visual ﬁ  eld 
defect that spares the central ﬁ  eld. In the optic neuritis treat-
ment trial, 11% of patients had a visual acuity of 20/20 or 
better (Beck et al 2003). Color vision can be assessed by 
using the Ishihara color plates or the American Optical Hardy-
Ritter-Rand (AOHRR) pseudoisochromatic color plates. Most 
patients with acquired optic neuropathy will have dyschroma-
topsia. However, some patients, especially those with ischemic 
optic neuropathies may have normal color vision at least in 
their intact visual ﬁ  eld areas. When assessing color vision, it 
is important to not only assess the number of plates recognized 
by each eye, but also the speed with which they are recognized 
and the patients’ subjective comparison between each eye. 
Dyschromatopsia can also occur in macular disease but in this 
case the visual acuity tends to be profoundly affected. A mild 
to moderate visual acuity loss in association with dyschroma-
topsia is a sensitive indicator of optic neuropathy.
A RAPD can be detected by performing the swinging 
light-pupil test. In the presence of bilateral symmetric optic 
neuropathy, a RAPD may be absent and the briskness of 
pupillary constriction to light will reﬂ  ect the degree of optic 
nerve dysfunction. When checking for RAPD, it is important 
to use a very bright light in a dark room to assess the full 
amplitude of pupillary response. A RAPD can be estimated 
subjectively by asking the patient about the difference in 
brightness of light presented in front of each eye.
Patients with optic neuropathy often have red color 
desaturation and a red-capped bottle can be presented to 
each eye and the patient can be asked about the difference 
in brightness of the red color. A positive response would be 
that the red color looks “faded”, “pink” or “washed out”.
Fundus examination may show normal, swollen, pale 
or anamolous optic disc. The optic disc is usually swollen 
in NAION and inﬂ  ammatory (non-demyelinating) optic 
neuritis. In demyelinating optic neuritis, however, the optic 
disc is normal in 65% of cases (retrobulbar neuritis). If disc 
swelling is present in demyelinating optic neuritis, it is usu-
ally mild and diffuse in nature. Severe disc swelling with the 
presence of hemorrhages and exudates is very atypical of 
demyelinating optic neuritis and should point to an alterna-
tive etiology such as NAION, inﬂ  ammatory, or inﬁ  ltrative 
optic neuropathy. In NAION, disc swelling can be sectoral 
or diffuse and typically associated with peripaillary hemor-
rhages. A small cup-to-disc ratio (also called disc at risk or 
congenitally anamolous) is seen in the other eye. Diffuse 
pallid or “chalky white” swelling with cotton wool spots is 
usually seen in AION due to GCA. Temporal pallor is seen in 
conditions that selectively affect the papillo-macular bundle 
such as toxic/nutritional and hereditary optic neuropathies.
The ophthalmologist should always look for evidence of 
uveitis such as cells in the anterior vitreous or signs of poste-
rior uveitis such as retinal vasculitis, retinitis, and choroiditis. 
This would indicate that the disc swelling is secondary to a 
uveitic process.
A pale optic disc indicates long-standing optic neuropa-
thy such as compressive, hereditary, toxic/nutritional optic 
neuropathies. This can also occur as a sequel of an acute 
inﬂ  ammatory or ischemic optic neuropathy. Sectoral pallor 
with retinal arteriole attenuation should point to a previous 
NAION. When optic atrophy is present, it is possible to detect 
slit-like or wedge-shaped defects in the peripapillary nerve 
ﬁ  ber layer. The red-free ophthalmoscope is most useful to 
detect these subtle changes.
Diffuse cupping with pallor occurs in the end stage fol-
lowing AION (Danesh-Meyer et al 2001). Occasionally, optic Clinical Ophthalmology 2007:1(3) 235
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disc cupping is seen and the disc appearance may resemble 
glaucomatous disc cupping. Pallor of the neuro-retinal rim 
is a speciﬁ  c but insensitive sign of non-glaucomatous cup-
ping. Cupping of the optic nerve head has been described 
in congenital optic disc anamolies, compressive optic 
neuropathy from large intra-cranial aneurysms or masses, 
hereditary optic neuropathy (dominant optic atrophy, Leber’s 
mitochondrial optic neuropathy), radiation optic neuropathy 
and methanol poisoning (Trobe et al 1980a, 1980b; Bianchi-
Marzoli et al 1995) The ophthalmologist should carefully 
consider these underlying causes before resorting to the 
diagnosis of “low tension glaucoma”.
An anamolous optic nerve indicates a congenital anamoly 
such as optic nerve hypopolasia, optic nerve coloboma, 
morning-glory disc anamoly and optic nerve drusen. These 
entities will not be discussed further and the discussion will 
be limited to acquired optic neuropathies.
Investigations
Visual ﬁ  eld testing
Visual ﬁ  led testing is an integral component of the neuro-
ophthalmic examination and is critical in the diagnosis of 
optic neuropathy. Both manual kinetic or automated static 
perimetry can be used. The visual ﬁ  eld defects in optic 
neuropathies can take several patterns including central, 
diffuse, arcuate, and altitudinal defect. The pattern of visual 
ﬁ  led defect is not speciﬁ  c of any etiology and almost any 
type of ﬁ  eld defect can occur with any optic neuropathy. 
However, altitudinal defects are more common in ischemic 
optic neuropathies and central, or cecocentral defects fre-
quently accompany toxic/nutritional and hereditary optic 
neuropathies. A cental scotoma affects central ﬁ  xation and 
is due to a lesion in the fovea or papillomacular bundle. A 
cecocentral sctoma extends from ﬁ  xation towards the blind-
spot and is due to invelvement of the papillomacular bundle 
arising from the fovea towards the optic disc. A hemianopic 
defect respecting the vertical midline indicates a lesion at or 
posterior the chiasm. A junctional scotoma, deﬁ  ned as ipsi-
lateral central ﬁ  eld defect and contralateral superotemporal 
ﬁ  eld defect indicates a compressive lesion at the junction 
of the optic nerve and the chiasm.
Contrast sensitivity
Contrast sensitivity is usually reduced in patients with optic 
neuropathy. Testing charts such as the perri-robson charts 
can be useful in patients with normal snellen visual acuity. 
The sensitivity and speciﬁ  city of this tool, however, is yet 
to be determined.
Electrophysiological tests
Visual evoked potential (VEP) can be abnormal in any optic 
neuropathy but it is no substitute to a careful clinical examina-
tion. VEPs measure the cortical activity in response to ﬂ  ash 
or pattern stimulus. They are abnormal in the presence of any 
lesion along the anterior visual pathway. Although VEP is 
not necessary in the diagnosis of optic neuropathy, it can be 
useful in patients with early or sub-clinical optic neuropathy 
who may have normal pupillary responses and no discernible 
optic disc changes on clinical examination. VEPs are used 
commonly in patients with demyelinating disease to detect 
occult optic nerve dysfunction and to identify a second site of 
involvement as part of the neurological assessment. Pettern 
ERG (PERG) can be abnormal in dysfunction of the macula 
or retinal ganglion cells, which do not contribute signiﬁ  cantly 
to the full ﬁ  eld ERG. Therefore, PERG can be useful in a 
patient with abnormal VEP to identify a macular lesion. 
A more recent technology, multifocal VEP, has been shown 
to be of useful values in detecting optic neuritis patients at 
high-risk patients to develop clinically deﬁ  nite multiple 
sclerosis (Fraser et al 2006). Panﬁ  eld eletroretinography can 
be useful to rule out diffuse retinal diseases such as retinitis 
pigmentosa and multifocal electroretinography can be useful 
to distinguish macular disease from optic neuropathy.
Optical coherence tomography (OCT)
OCT is a new technology that uses low coherence light to 
penetrate tissue and a camera to analyze the reﬂ  ected image. 
By performing circular scans around the optic nerve head, 
the peripapillary nerve ﬁ  ber layer can be analyzed. This has 
been useful in the follow up of patients with optic neuritis, 
traumatic optic neuropathy, and Leber’s hereditary optic 
neuropathy (Medeiros et al 2003; Barboni et al 2005; Lim 
et al 2005; Costello et al 2006; Pro et al 2006; Trip et al 
2006). OCT can also be used to document peripaillary nerve 
ﬁ  ber layer thickening in subtle NAION cases and to follow 
up resolution of disc edema (Savini et al 2006).
Speciﬁ  c diagnosis
Acute demyelinating optic neuritis
Because optic neuritis can be the initial manifestation of 
multiple sclerosis (MS), its recognition is of important prog-
nostic value. Optic neuritis is more common in females with 
a peak age of onset between 30–40 years (Beck et al 2003). 
Magnetic resonance imaging (MRI) of the brain is needed 
to detect the presence of white matter lesions. The risk of 
developing clinically deﬁ  nite multiple sclerosis over 10 
years is 56% if one or more baseline lesion 3 mm diameter Clinical Ophthalmology 2007:1(3) 236
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is found, whereas the risk in normal MRI is 22% (Figure 1). 
The risk is low (5%) in males with severe disc edema with 
peripaillary hemorrhages and normal MRI (Beck et al 2003). 
Initiating treatment with beta-1a interferon should be strongly 
considered in high-risk patients since this has been found to 
decrease the risk of conversion to clinically deﬁ  nite multiple 
sclerosis by 50% (Beck et al 2002).
Optic neuritis improves in 90% of cases over several 
weeks to near normal visual acuity (Beck 1995). The use of 
intravenous steroids was found to hasten the visual recovery 
but not the ﬁ  nal visual outcome (Beck 1995). However, the 
early use of steroids may be warranted to minimize axonal 
loss of the optic nerve, which has been found to occur early 
in the disease (Arnold 2005; Trip et al 2005; Costello et al 
2006). Lack of improvement after about 4–6 weeks with 
or without steroids is atypical of optic neuritis and should 
prompt searching for an alternative causes such as inﬂ  amma-
tory (sarcoid, vasculitis), inﬁ  ltrative and compressive. In such 
cases, the recommended additional investigations include 
spinal tap, complete blood count, antinuclear antibodies 
(ANA), chest radiographs, angiotensin converting enzyme 
levels (ACE), and anti-neutrophil cytoplasmic antibodies 
(ANCA) (Lee et al 2000).
Optic neuritis in children is classically thought to dif-
fer from adult optic neuritis by frequent bilateral involve-
ment and disc swelling, and more severe initial vision 
Table 1
Type of optic   Onset  Pattern of visual ﬁ  eld   Ophthalmoscopic  Additional 
neuropathy   loss  ﬁ  ndings  features
Demyelinating  Acute  Central, cecocentral, arcuate  75% normal disc   Neurological signs of brain stem
      (retrobulbar)  (diplopia, ataxia, weakness) or
        spinal cord involvement 
        (leg weakness,  bladder symptoms, 
        paresthesias, abnormal MRI)
Non-arteritic   Acute  Arcuate, altitudinal  Swollen disc (usually   Crowded (anamalous) disk,
Ischemic      sectoral) with disc  systemic vascular risk factors
     hemorrhages (diabetes,  hypertension,
       hyerlipedemia)
Arteritic   Acute  Arcuate  Pallid swelling    Headache, jaw claudications,
Ischemic      of the disc  transient visual loss or
        diplopia, myalgias, fever, weight
        loss, High ESR and CRP
Inﬂ  ammatory   Acute,   Arcuate, central,   Swollen disc  Features of auto-immune
  sub-acute  cecocentral    diseases (skin rash, arthritis,
       Raynaud’s  phenomenon),
       exquisite  responsiveness
        to systemic steroids
Inﬁ  ltrative  Acute,   Arcuate, hemianopic   Normal or   Systemic malignancy may be
  subacute    swollen disc  present, MRI may show optic
        nerve or meningeal inﬁ  ltration
Compressive  Chronic  Arcuate, hemianopic  Normal or pale   MRI will show a
     disc  compressive  mass
Toxic/nutritional  Acute, subacute  Central, cecocentral  Normal or mildly   History of drug use (ethambutol,
  or chronic    swollen disc  alcohol) 
Hereditary  Chronic (dominant  Central, cecocentral  Pale (dominant and recessive)  Onset in childhood with positive
  and recessive), acute    or mildly swollen with  family history, Mitochondrial
  or subacute (Leber’s)    peripapillary telengiectatic  DNA testing may reveal
      vessels (Leber’s)  Leber’s mutataion
Traumatic  Acute  Arcaute, central or  Normal  Head or facial trauma
   hemianopic
Radiation  Acute  Arcuate, hemianopic  Normal  History of radiation to the
        brain or orbit, MRI may show
        enhancement of the optic
        nerve with Gadolinium
Paraneoplastic  Subacute,  Central  Swollen disc  Associated small-cell lung
  chronic      carcinoma, CRMP-5 marker
        may be positive, paraneoplastic
       cerebellar  syndromeClinical Ophthalmology 2007:1(3) 237
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loss. A history of viral infection or vaccination is common 
(Figure 2). Other neurological manifestations may occur if 
there is concurrent acute disseminated encephalomyelitis 
(Bangsgaard et al 2006). MRI of the brain and orbit is 
recommended to rule out demyelination, and meningeal 
enhancement seen in infectious or non-infectious menin-
gitis. Contrary to the common notion that childhood optic 
neuritis is less likely to be associated with multiple sclerosis 
(Lucchinetti et al 1997), a recent report found an association 
with MS in 36% of patients with optic neuritis, especially 
with bilateral involvement (Wilejto et al 2006).
Neuromyelitis optica (Devic’s disease)
When optic neuritis is preceded or followed by transverse or 
ascending myelopathy often causing paraplegia, the condition 
is referred to as neuromyelitis optica (NMO). This condi-
tion is more common in young patients with a predilection 
for Asians and Africans (Cabre et al 2001; Nakashima et al 
2006). The visual loss is often severe, bilateral and may 
precede or follow the myelopathy. The interval between 
myelopathy and optic neuritis can be months to years. MRI 
of the spine will show demyelination extending over 3 or 
more vertebral segments. There is a debate about whether 
NMO is simply a sub-type of MS (Rubiera et al 2006). 
Although, lesions outside the optic nerve and spinal cord were 
considered incompatible with NMO, the criteria of diagnosis 
have been revised recently to allow for the presence of MRI 
brain lesion “not compatible with MS” (Pittock et al 2006; 
Wingerchuk et al 2006). A serum marker, NMO Ig-G, has 
been found useful to distinguish NMO from other related 
disorders such as MS (Lennon et al 2004).
Non-arteritic ischemic optic neuropathy 
(NAION)
NAION can occasionally be confused with acute demyelin-
ating optic neuritis. There are some features that may help 
distinguishing the two conditions. The presence of severe 
disc edema with hemorrhages is characteristic of NAION and 
atypical of optic neuritis (Figure 3). Patients with NAION are 
usually over 50 years old and have systemic vascular risk fac-
tors such as diabetes, hypertension, and smoking (Tsai et al 
1998; McCulley et al 2005). Nevertheless, NAION can occur 
in young patients (below 45 years) and patients who lack any 
vascular risk factors. In young patients, it has been associated 
with hypercholesterolemia and hyperhomocysteinemia (Pianka 
et al 2000; Deramo et al 2003). Visual acuity can be normal or 
severely affected. The visual ﬁ  eld defect is usually inferonasal 
arcuate or altitudinal. The optic nerve head in the other eye 
is often has small cup-to-disc ratio (0.1 or less) (Burde 1993; 
Feldon 1999). This optic nerve head conﬁ  guration seems to 
play a more important role than the systemic risk factors (Tsai 
et al 1998). Recent reports have linked NAION to the sleep 
apnea syndrome (Mojon et al 2002; Palombi et al 2006), but 
it is unknown whether treatment of sleep apnea can prevent 
NAION (Behbehani, Mathews et al 2005).
Visual acuity usually remains static or improves slightly 
in the vast majority of patients with NAION (Arnold and 
Hepler 1994). In a small subset of patients, visual acuity 
may actually worsen over the ﬁ  rst few weeks (progressive 
NAION) (Sergott et al 1989; Spoor et al 1993; Arnold and 
Hepler 1994). This progressive phase may cause a diag-
nostic difﬁ  culty but it rarely lasts more than 3–4 weeks 
and is then followed by stabilization of visual function. 
Bilateral simultaneous involvement is very unusual of 
NAION and but can occur during a hypotensive episode 
such as blood loss or over-dosing of anti-hypertensive 
medications (Hayreh 1999). Recurrence in the same eye is 
uncommon with a risk of 5% (Hayreh et al 2001). The risk 
A
B
Figure 1 (A) Axial MRI of the brain (FLAIR sequence) showing the classic peri-
ventricular white matter lesions seen in MS. (B) Sagittal MRI showing peri-collosal 
white matter lesions also known as “Dawson’s ﬁ  ngers”.
Figure 2 An 11 year old boy with sudden onset of visual loss 2 weeks following 
a viral upper respiratory tract infection. Bilateral disc swelling was seen in the 
right (A) and left (B) disc. Visual acuity improved over 1 week spontaneously from 
counting ﬁ  ngers to 20/20 in both eyes.
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of later involvement in the follow eye within 5 years is 15% 
(Newman et al 2002).
In posterior ischemic optic neuropathy (PION) there 
is no disk swelling. PION can occur in severe blood 
loss, hypotension, hemodialysis, anemia, and after long 
surgeries, such as spinal surgeries, in which the patient 
is positioned prone (Buono et al 2003; Murphy 2003; 
Hayreh 2004). The visual loss is often bilateral but can be 
asymmetrical. Pupillary responses to light will be slug-
gish, which helps distinguish PION from a cortical cause 
of vision loss.
Arteritic ischemic optic neuropathy 
(AION)
In patients over 60 year old with features of ischemic optic 
neuropathy, the ophthalmologist should strongly consider 
the possibility of giant cell arteritis (GCA). Careful medical 
history should be obtained, inquiring about temporal pain, 
jaw claudications, transient visual or diplopia, fever, weight 
loss, myalgias and fatigue (Hayreh et al 1998b). Some 
patients may not have the constitutional symptoms and 
have only visual symptoms (occult GCA) (Liu et al 1994; 
Hayreh et al 1998a). Other clinical features that may help 
distinguishing patients with AION from NAION include 
cup-to-disk ratio of greater than 0.2 in the other eye, early 
massive or bilateral simultaneous visual loss, markedly 
pallid disk edema often described as “chalky-white” swell-
ing in 68.7% of cases, and choroidal infarcts (Figure 4) 
(Hayreh et al 1998a, 1998b). Rarely, the optic disc can 
look normal (PION) (Sadda et al 2001). End-stage optic 
disc appearance of patients with AION is characterized by 
marked cupping with pallor and should not be confused 
Figure 3 A 57 year old patient with history of hypertension, diabetes and hypercholesterolemia and NAION in his right eye. There is pallid swelling of the right disc with 
hemorrhage superiorly. The left optic disc has a cup to disc ratio of 0.1 (not shown).Clinical Ophthalmology 2007:1(3) 239
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with glaucomatous cupping (Danesh-Meyer et al 2001). 
The superﬁ  cial temporal arteries should be palpated and 
the pulse felt. Patients with GCA have a “cord-like” feel 
with reduced pulses.
Laboratory evaluation should include complete blood 
count, erythrocyte sedimentation rate (ESR), and C-reactive 
protein (CRP). ESR is elevated in GCA but 2–30% of patients 
with biopsy-proven GCA will have normal ESR (Brittain et al 
1991; Liu, Glaser et al 1994; Hayreh et al 1997; Salvarani 
and Hunder 2001). Elevated CRP was found to be more 
sensitive (97.5%) than ESR (76%–86%) for the detection 
of GCA. ESR and CRP combined give the best speciﬁ  city 
(97.0%) and sensitivity (99%) for diagnosis (Hayreh et al 
1997; Parikh et al 2006). Thrombocytosis is another use-
ful feature that can complement ESR and CRP (Lincoff 
et al 2000; Costello et al 2004).
Steroid treatment should be instituted in patients who 
are considered at high risk to have GCA based on the 
clinical and laboratory features. Untreated GCA will cause 
visual loss in the fellow eye in about a third of cases with 
the risk highest in the ﬁ  rst 4 weeks. Either oral (80–120 mg 
prednisone) or intravenous (1 gram methyleprdnisolone) for 
3–5 days followed by oral steroids can be used. There is no 
evidence that either route of administration is more effective 
in preventing possible early visual deterioration (Hayreh and 
Zimmerman 2003). There are reports of the successful use of 
heparin if visual deterioration occurs despite being on steroid 
treatment (Buono et al 2004).
Deﬁ  nitive diagnosis of AION is established by temporal 
artery biopsy and histopathological conﬁ  rmation. Although 
the inﬂ  ammation can be seen histopathologically in the 
vessels for weeks despite steroid therapy, temporal artery 
biopsy should be performed as soon as the patient is started 
on steroids to avoid equivocal results. Jaw claudications and 
neck pain are signiﬁ  cant indicators of a positive temporal 
artery biopsy independent of the ESR and CRP (Hayreh et al 
1997) The odds ratio for a positive temporal artery biopsy 
was 9.0 times greater with jaw claudications, 3.3 greater 
with neck pain, and 3.2 greater with an elevated ESR and 
CRP (Hayreh et al 1997). Biopsy can be performed on one 
Figure 4 Disc swelling in GCA. Note pallid disc swelling with hemorrhages and an adjacent area of choroidal infarction (arrow) (courtesy of Peter J Savino, MD).Clinical Ophthalmology 2007:1(3) 240
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side and if it is negative and the index of suspicion of GCA 
is high, a biopsy is performed the contra-lateral side. Some 
authors advocate bilateral temporal artery biopsies at the 
onset because an overall chance of discordance of 4%–5% 
(Danesh-Meyer et al 2000; Pless et al 2000).
Inﬂ  ammatory (non-demyelinating) optic 
neuropathy
This category comprises many entities in which the optic 
nerve is involved by either an ocular or systemic inﬂ  am-
matory process. Optic disc swelling frequently occurs with 
posterior uveitis and retinitis. Therefore, when evaluating 
optic disk swelling, it is useful to look for evidence of anterior 
or posterior segment inﬂ  ammation. Optic neuropathy can 
also occur in the context orbital inﬂ  ammatory disease (orbital 
pseudotumor). MRI of the orbit will show inﬂ  ammation of 
the optic nerve sheath (optic perineuritis) (Fay et al 1997).
The optic nerve can be involved in a variety of systemic 
auto-immune and infectious disorders such as sarcoidosis, 
systemic lupus erythematosus, Behcet’s disease inﬂ  amma-
tory bowel disease, Sjogren’s syndrome Wegener’s granu-
lomatosis, syphilis, Lyme disease and cat-scratch disease 
(Jabs et al 1986; Wise and Agudelo 1988; Kansu et al 1989; 
Belden et al 1993; Han et al 2006).
Auto-immune optic neuropathy is a recurrent, steroid-
responsive optic neuropathy. The anti-nuclear antibody 
(ANA) and anticardiolipin antibody are frequently positive 
(Kupersmith et al 1988; Frohman et al 2003). The diagnosis 
is made by performing a skin biopsy, which often shows evi-
dence of vasculitis when studied with immunoﬂ  orescence.
Chronic relapsing inﬂ  ammatory optic neuropathy is 
another entity characterized by recurrences and steroid-
responsiveness. The syndrome can behave as granulomatous 
optic neuropathy and may require long-term immunosup-
pressive therapy (Kidd et al 2003).
Some of the features that should raise the suspicion of 
an inﬂ  ammatory optic neuritis include lack of spontaneous 
improvement of visual function after 30 days, or exquisite 
steroid-responsiveness and steroid-dependency. In such 
cases, a spinal tap and additional laboratory studies directed 
by the history and neuro-ophthalmic examination are indi-
cated (see discussion under demyelinating optic neuritis).
Inﬁ  ltrative optic neuropathies
The optic nerve can be inﬁ  ltrated in systemic malignancies 
such as lymphoma, leukemia, multiple myeloma, and 
carcinoma (Brown et al 1981; Brazis et al 1990; Behbehani, 
Vacarezza et al 2005; Shimada et al 2006). The optic disc 
can be swollen or normal in appearance (Figure 5). MRI 
of the brain and orbit may show meningeal and optic 
nerve enhancement. Spinal tap is recommended in cases of 
suspected CNS malignancy but more than one spinal tap may 
be needed to detect malignant cells (van Oostenbrugge and 
Twijnstra 1999) In case of localized optic nerve inﬁ  ltration 
with no evidence of systemic disease, histopathological 
diagnosis may require direct optic nerve sheath biopsy 
(Behbehani, Vacarezza et al 2005).
Compressive optic neuropathy
In compressive optic neuropathy, visual loss is usually 
gradual and progressive. Common causes include orbital 
and intracranial meningiomas, pituitary adenomas, intra-
cranial aneurysms, craniopharyngiomas, and gliomas of the 
anterior visual pathway (Figure 6). Vision loss, however, 
can be fast and dramatic in pituitary apoplexy, or ruptured 
aneurysm. Visual ﬁ  eld testing aids in the localization of 
the lesion and neuro-imaging with MRI of the brain and 
orbit is essential.
Compressive optic neuropathy can also occur in thyroid 
eye disease and can present as asymmetric progressive visual 
loss. This will require prompt therapy (orbital radiation, 
orbital decompression, high-dose systemic steroids).
Hereditary optic neuropathy
The hereditary optic neuropathies are a broad category 
including autosomally inherited diseases (dominant, reces-
sive, X-linked) and diseases caused by inheritance of defec-
tive mitochondrial genome. Mitochondrial dysfunction may 
be a ﬁ  nal common pathway among these disorders (Newman 
2005; Atkins et al 2006). Hereditary optic neuropathies can 
be isolated or associated with other neurological signs and 
symptoms.
Patients with dominant optic neuropathy (Kjers’ type) 
often present in the ﬁ  rst decade of life with bilateral sym-
metric visual loss. Visual acuity can range from 20/20 to 
20/400 (Hoyt 1980; Das et al 2006). Visual ﬁ  eld testing 
frequently reveals bilateral central or cecocentral scotomas. 
In some cases, a central hemianopic bitemporal visual ﬁ  eld 
defect is found, which in the absence of positive family his-
tory may erroneously lead to a search for a chiasmal lesion 
(Manchester and Calhoun 1958). Patients will have color 
vision deﬁ  cit along the tritan (blue-yellow) axis. The optic 
disc will show temporal pallor and in some cases severe 
excavation and cupping. There various responsible genetic 
mutations occur in the OPA1 gene located on the chromo-
some 3 q region (Votruba 2004).Clinical Ophthalmology 2007:1(3) 241
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Recessive optic neuropathy is rare and tends to present 
in the ﬁ  rst year of life (Francois 1976). It can be associated 
with diabetes mellitus, diabetes inspidus, and deafness 
(Wolfram syndrome) (Ajlouni et al 2002). An X-linked 
optic atrophy has also been described and the genetic muta-
tion has been localized to Xp11.4–Xp11.2 (OPA2) (Katz 
et al 2006). Optic neuropathy can also occur in neurological 
conditions such as spinocerebellar degeneration, Friedriech’s 
ataxia, and olivo-ponto-cerebellar atrophy.
Leber’s hereditary mitochondrial optic neuropathy 
(LHON) classically presents with acute unilateral, painless, 
visual loss. However, some cases may stay asymptom-
atic or have a chronic course (Kerrison 2005). Sequential 
bilateral involvement may occur weeks or months later. 
Visual ﬁ  led defects tend to be central or cecocentral as the 
papillo-macular bundle is ﬁ  rst and most severely affected 
(Barboni et al 2005). Fundoscopy may show disk swelling, 
thickening of the peripapillary retinal nerve ﬁ  ber layer and 
peripapillary retinal telangectatic vessels which do not leak 
on ﬂ  ourescin angiography (Figure7). Occasionally, optic 
nerve pallor can be seen initially. Because of the wide age 
range (6–80 years old) at which LHON may present, it is 
frequently misdiagnosed (Ajax and Kardon 1998). Young 
patients are often diagnosed as optic neuritis and older 
patients as ischemic or inﬁ  ltrative optic neuropathy. MRI 
may show optic nerve enhancement and white matter lesions, 
which may add to the diagnostic difﬁ  culties (Paulus et al 
1993; Vaphiades and Newman 1999). Therefore, a high index 
of suspicion is essential. Some patients may spontaneously 
improve to normal or near normal visual acuity (Nakamura 
and Yamamoto 2000).
LHON has 4 primary mitochondrial genome mutations; 
G11778A, G3460A and T14484C and T10663C. The disease 
affects males more than females with a ratio of 2.5:1 for 
the G11778A and G3460A mutation and 6:1 ratio for the 
T14484C mutation (Riordan-Eva et al 1995). The frequencies 
Figure 5 A 55 year old women with chronic disc swelling and optic neuropathy in the right eye. MRI showed enhancement of the intracranial nerve.  An extensive work up, 
including a spinal tap, was negative.  An optic nerve sheath biopsy showed optic nerve lymphoma with no systemic involvement.Clinical Ophthalmology 2007:1(3) 242
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of mutation may vary across different countries and newer 
mutations have been described worldwide (Zhadanov et al 
2005; Houshmand et al 2006). Some patients may demon-
strate neurological manifestations such as peripheral neuropa-
thy, ataxia, dystonia and cardiac conduction defects (Bower 
et al 1992; Murakami et al 1996; Watanabe et al 2006). These 
patients fall in the spectrum mitochondrial encephalomyelop-
athies and their clinical manifestations may vary considerably 
(Gropman et al 2004; Blakely et al 2005).
Toxic-nutritional optic neuropathies
Optic nerve dysfunction can be caused by various drugs, toxins 
and nutritional deﬁ  ciencies. The most common offenders 
are ethambutol, amiodarone, methanol, ethanol and tobacco 
(DeVita et al 1987; Purvin et al 2006). Similar to hereditary 
optic neuropathies, toxic-nutritional optic neuropathies are also 
characterized by selective maculo-papillar bundle involve-
ment, leading to central or cecocentral scotomas. Ethambutol 
causes optic neuropathy in 1% of patients using the anti-tuber-
culous medication. Although the dosage of 25 mg/kg/day for 
2 months followed by 15 mg/kg/day maintenance doses is 
considered safe, toxicity has been reported at below this dos-
age (Tsai and Lee 1997). Patients with low zinc levels were 
found to be more vulnerable to develop optic neuropathy (De 
Palma et al 1989). The visual symptoms usually start 2–8 
months after the drug is started. Pupillary abnormalities can be 
subtle, and visual evoked potential may be needed to conﬁ  rm 
the diagnosis. The diagnosis is often made late when optic 
nerve pallor has already set in and vision is severely affected. 
The drug should be stopped as soon as the diagnosis is made, 
although in advanced cases vision continues to deteriorate 
even following drug cessation.
The anti-arrhythmic drug amiodarone can cause bilateral 
optic neuropathy. Because patients using this drug have sys-
temic vascular risk factors, there is still controversy whether 
patients affected may simply have NAION. Some of the 
clinical features that may help distinguish this entity from 
NAION are the bilateral simultaneous onset, the insidious 
nature of vision loss, and the protracted disc edema which 
can last for months (Murphy and Murphy 2005; Purvin et al 
2006). The disc edema in NAION usually resolves within 
6–8 weeks.
Other medications which can cause toxic optic neuropathy 
include methotrexate, cyclosporine, vincristine, cisplatin and 
chloramphenicol (Godel et al 1980; Walter et al 2000; Wang 
et al 2000; Clare et al 2005; Weisfeld-Adams et al 2005).
Tobacco-alcohol amblyopia is a term used for a condition 
that may be due both the toxic effect of the tobacco and a 
nutritional deﬁ  ciency state. Because many patients who abuse 
alcohol and tobacco do not get optic neuropathy, the mecha-
nism is unlikely to be a direct insult to the optic nerve. A more 
plausible mechanism is that genetic and nutritional deﬁ  ciency 
factors increase the susceptibility for optic neuropathy for 
the effects of certain toxins. Deﬁ  ciency of thiamine (B1), 
riboﬂ  avin (B2), folate, B12 and B6 have all been associated 
with optic neuropathy (Rizzo and Lessell 1993; Golnik and 
Schaible 1994; Sadun et al 1994; Hsu et al 2002). Patients 
who follow high protein, ketogenic and low carbohydrate 
diet are at risk for developing thiamin deﬁ  ciency. Simi-
larly, patients who have undergone gastrointestinal surgery 
may develop optic neuropathy due interference with the 
absorption of vitamin B12.
Figure 6 An axial contrast-enhanced MRI of the orbit showing enhancement of 
the intra-orbital and intra-canalicular optic nerve in a lady with optic nerve sheath 





Figure 7 A 55 year old lady carrier of the 3460 G LHON mitochondrial mutation,  
with bilateral disc swelling (top ﬁ  gure). Automated 24–2 perimetry (middle ﬁ  gure) 
shows bilateral arcuate defects and 10–2 perimetry shows bilateral central sco-
tomas (bottom ﬁ  gure). The patient is a carrier the 3460 G LHON mitochondrial 
mutation.Clinical Ophthalmology 2007:1(3) 243
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Radiation optic neuropathy (RON)
Patients with RON can present with vision loss, months or 
years following history of radiation exposure to the brain or 
orbit. The risk increases in patients who had also received 
chemotherapy (Kline et al 1985). The mechanism of RON 
is ischemia caused by endothelial cell injury from radiation. 
The optic disc is usually normal but can be swollen. MRI of 
the orbit may show optic nerve enhancement with gadolinium 
(Guy et al 1990; Lessell 2004). Patients may also have radia-
tion retinopathy with retinal hemorrhages, cotton wool spots, 
exudates and macular edema. Because many of those patients 
were treated for brain or orbital tumors, recurrent tumor is 
initially the main consideration when patients become symp-
tomatic. There is no treatment of proven efﬁ  cacy for RON. 
Hyperbaric oxygen, steroids, antiplatelet drugs, and antico-
agulants have all been used with limited success (Barbosa 
et al 1999; Danesh-Meyer et al 2004; Boschetti et al 2006). 
The visual prognosis is poor with 45% of eyes ending with 
no light perception visual acuity (Lessell 2004).
Traumatic optic neuropathy
Traumatic optic neuropathy presents with typical signs 
and symptoms. Patients usually had suffered craniofacial 
trauma but occasionally mild orbital or eye injury (Hou and 
Murphy 2004; Nishi et al 2006). A RAPD is the main clue 
to the diagnosis. CT scan of the orbit is recommended to 
detect any bony fractures, fractures of the optic canal, and 
acute orbital hemorrhages. High-dose steroid therapy was 
adopted as a treatment because of their beneﬁ  cial effect in 
studies on spinal cord injuries. Subsequently, however, it was 
shown that high-dose steroids may be harmful to the optic 
nerve if started 8 hours after the injury (Steinsapir 2006). 
In a non-randomized trial, no clear beneﬁ  t was found with 
either steroids or surgical decompression of the optic canal 
(Levin et al 1999). There are anecdotal reports of beneﬁ  cial 
outcome of surgery in cases of optic canal fracture and optic 
nerve sheath hematoma (Jiang et al 2001; Wohlrab et al 2002; 
Rajiniganth et al 2003).
Paraneoplastic optic neuropathy
Optic neuropathy can occur as a remote effect of both small 
cell and non-small cell lung carcinoma of the lung (Asproudis 
et al 2005; Sheorajpanday et al 2006). Some patients may 
have a concurrent paraneoplastic cerebellar syndrome of dys-
arthria and ataxia (Luiz et al 1998; Thambisetty et al 2001). 
Patients often have bilateral disc swelling and progressive 
visual loss before the diagnosis of the systemic malignancy 
is made. The collapsing response-mediating protein (CRMP-
5) has been found recently to be a useful marker in the 
diagnosis of this condition in patients with lung carcinoma 
(Yu et al 2001; Calvert 2006).
Conclusion
Optic neuropathy can be caused by demyelination, inﬂ  amma-
tion, ischemia, inﬁ  ltration, compression, and hereditary and 
toxic/nutritional causes. Careful clinical evaluation is essen-
tial to rule in the diagnosis of optic neuropathy. Recognition 
of same entities can not only alter the visual prognosis but also 
the neurological prognosis. Some additional tests particularly 
visual ﬁ  eld testing and neuro-imaging are very useful in the 
clinical evaluation. The ophthalmologist should be familiar 
with the various entities that can cause optic neuropathy. With 
careful clinical evaluation and appropriate investigations, a 
speciﬁ  c diagnosis can be made in most cases.
Note
The author has no relevant ﬁ  nancial interest in this article.
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